Skip to main content

CYBN

Stock

CYBN

Stock
Health Care
Biotechnology

Performance overview

CYBN Price
Price Chart

Forward-looking statistics

Beta
0.49
Risk
66.72%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Company info

SectorHealth Care
IndustryBiotechnology
Employees50
Market cap$220.2M

Fundamentals

Enterprise value
Revenue
Revenue per employee
Profit margin
Debt to equity

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)
Dividend per share
Revenue per share
Avg trading volume (30 day)
Avg trading volume (10 day)
Put-call ratio

Macro factor sensitivity

Growth+12.3
Credit-3.4
Liquidity-8.4
Inflation+8.7
Commodities+7.3
Interest Rates-1.7

Valuation

Dividend yield0.00%
PEG Ratio
Price to sales
P/E Ratio-1.07
Enterprise Value to Revenue
Price to book

Upcoming events

Next earnings dayJune 26, 2024
Next dividend day
Ex. dividend day

News

Cybin Inc. (CYBN) Loses -25.81% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Cybin Inc. (CYBN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Investment Research (March 4, 2025)
Cybin, Deepak Chopra Announce Partnership For Psychedelics Awareness And Education

Psychedelics-focused biotech company Cybin Inc. (NYSE:CYBN) announced that it has formed a partnership with The Chopra Foundation, a not-for-profit founded by alternative medicine and new age author Deepak Chopra. "The Foundation is working closely with Cybin to support education and awareness about its groundbreaking research to harness the potential of psychedelic therapies in mental health,' the organization stated in a press release.

Benzinga (February 16, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free